Medicon Valley Biomedical Newsletter

Active Biotech AB has announced the successful completion of three Phase I clinical studies of ANYARA for the treatment of advanced non-small cell lung cancer, renal cell cancer, and pancreatic cancer...

ALK-Abelló A/S has signed an agreement with Schering-Plough on a strategic alliance to develop and commercialise ALK-Abelló's tablet-based allergy immunotherapies in the USA, Canada and Mexico. Th...

Bavarian Nordic A/S has announced that its US-based subsidiary BN ImmunoTherapeutics Inc. has received approval from the US Food and Drug Association, FDA, to start clinical trials with their breast c...

Bavarian Nordic A/S has announced that the United States patent and trademark office has issued a notice of allowance on one of its patent applications which, when it issues, will further strengthen t...

BioGaia AB has signed an agreement with the baby food company Semper AB giving Semper the rights under the name Semper Magdropper, to sell BioGaia´s probiotic drops in Sweden and Norway. BioGai...

BioInvent International AB and ThromboGenics NV have announced that they have received a EUR 2 million grant from the European Union for the joint development of a new class of anti-angiogenesis agent...

BioInvent International AB has announced that it has entered into a strategic collaboration with Genentech Inc. to co-develop and commercialise BioInvent´s proprietary antibody candidate, BI-204, for ...

CellaVision AB has extended their exclusive distribution agreements with Sysmex Europe and Sysmex America for another three years in order to meet the demand for automated systems for digital cell mor...

CellaVision AB has received the first order for a digital cell morphology system from St. Michael's Hospital, Toronto. Additionally, a multi-system order was placed by Hamilton Healthcare Sciences...

Scientists and doctors from Copenhagen University and Aarhus University Hospital may have found a simple solution to test the extent of bladder cancer in a patient, a urine test. Every time a t...

DuoCort AB has announced the successful completion of a EUR 663.000, financing for the next phase of development of its Orphan-designated hydrocortisone dual-release tablet for the treatment of adren...

Evolva Biotech SA has announced that it has received a EUR 20. million award from the United States Defense Threat Reduction Agency, for the discovery and development of therapeutics that improve the ...

iClin Solutions AB, a company newly established and organised to exploit the competence in the field of intelligent solutions for cancer treatment, has announced its expansion of portfolio. The compan...

Lundbeck A/S's product Cipralex has been approved in the EU for the treatment of obsessive compulsive disorder, OCD, by the Swedish Medical Products Agency acting as reference member state for the Eur...

A new Danish biotech company, a spin off from the Technical University of Denmark ,DTU, will research for new compounds for the pharmaceutical industry among the more than 30,000 micro fungi growing o...

NeuroSearch A/S and GlaxoSmithKline, GSK, have initiated Phase II clinical development of drug candidate NS2359 in patients diagnosed with major depressive disorder. The studies will be conducted in m...

NNE A/S has reached an agreement with the health care group Fresenius ProServe to acquire its subsidiary, the Germany-based engineering company Pharmaplan GmbH. The two companies will unite under the ...

Pharmexa-Epimmune, a subsidiary of Pharmexa A/S, and Ichor Medical Systems of San Diego, California have entered into a collaborative agreement and have agreed to licensing terms for Pharmexa's HE...

ViroGates A/S has entered into agreements with Hvidovre Hospital in Denmark to supply the country's largest HIV centre with its first-in-class HIV disease monitoring test. Beginning in January 200...